Your browser doesn't support javascript.
loading
Preservation of kidney function in kidney transplant recipients by alkali therapy (Preserve-Transplant Study): rationale and study protocol.
Wiegand, Anna; Ritter, Alexander; Graf, Nicole; Arampatzis, Spyridon; Sidler, Daniel; Hadaya, Karine; Müller, Thomas F; Wagner, Carsten A; Wüthrich, Rudolf P; Mohebbi, Nilufar.
Afiliación
  • Wiegand A; Division of Nephrology, University Hospital Zurich, Zurich, Switzerland.
  • Ritter A; Division of Nephrology, University Hospital Zurich, Zurich, Switzerland.
  • Graf N; Graf Biostatistics, Wintherthur, Switzerland.
  • Arampatzis S; Department of Nephrology and Hypertension, University Hospital Berne, Berne, Switzerland.
  • Sidler D; Department of Nephrology and Hypertension, University Hospital Berne, Berne, Switzerland.
  • Hadaya K; Division of Nephrology, University Hospital Geneva, Geneva, Switzerland.
  • Müller TF; Division of Nephrology, University Hospital Zurich, Zurich, Switzerland.
  • Wagner CA; Institute of Physiology, University of Zurich, Zurich, Switzerland.
  • Wüthrich RP; Division of Nephrology, University Hospital Zurich, Zurich, Switzerland.
  • Mohebbi N; Division of Nephrology, University Hospital Zurich, Zurich, Switzerland. Nilufar.mohebbi@usz.ch.
BMC Nephrol ; 19(1): 177, 2018 07 13.
Article en En | MEDLINE | ID: mdl-30001705
BACKGROUND: Graft survival after kidney transplantation has significantly improved within the last decades but there is a substantial number of patients with declining transplant function and graft loss. Over the past years several studies have shown that metabolic acidosis plays an important role in the progression of Chronic Kidney Disease (CKD) and that alkalinizing therapies significantly delayed progression of CKD. Importantly, metabolic acidosis is highly prevalent in renal transplant patients and a recent retrospective study has shown that metabolic acidosis is associated with increased risk of graft loss and patient death in kidney transplant recipients. However, no prospective trial has been initiated yet to test the role of alkali treatment on renal allograft function. METHODS: The Preserve-Transplant Study is an investigator-initiated, prospective, patient-blinded, multi-center, randomized, controlled phase-IV trial with two parallel-groups comparing sodium bicarbonate to placebo. The primary objective is to test if alkali treatment will preserve kidney graft function and diminish the progression of CKD in renal transplant patients by assesing the change in eGFR over 2 years from baseline. Additionally we want to investigate the underlying pathomechanisms of nephrotoxicity of metabolic acidosis. DISCUSSION: This study has the potential to provide evidence that alkali treatment may slow or reduce the progression towards graft failure and significantly decrease the rate of end stage renal disease (ESRD), thus prolonging long-term graft survival. The implementation of alkali therapy into the drug regimen of kidney transplant recipients would have a favorable risk-benefit ratio since alkali supplements are routinely used in CKD patients and represent a well-tolerated, safe and cost-effective treatment. TRIAL REGISTRATION: ClinicalTrials.gov NCT03102996 . Trial registration was completed on April 6, 2017.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Trasplante de Riñón / Bicarbonato de Sodio / Álcalis / Receptores de Trasplantes / Riñón Tipo de estudio: Guideline / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: BMC Nephrol Asunto de la revista: NEFROLOGIA Año: 2018 Tipo del documento: Article País de afiliación: Suiza

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Trasplante de Riñón / Bicarbonato de Sodio / Álcalis / Receptores de Trasplantes / Riñón Tipo de estudio: Guideline / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: BMC Nephrol Asunto de la revista: NEFROLOGIA Año: 2018 Tipo del documento: Article País de afiliación: Suiza